STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to … keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup or three of stimulation. Our choice today is coconut rum. Meanwhile, here are some items of interest to get you going. Have a wonderful day and do drop us a line when you hear something juicy. … Ever since the U.S. Department of Treasury proposed to limit U.S. investment in the Chinese biotech industry last week, players across the U.S. are arguing over the significance of the restrictions, STAT explains. The main debate to date had been over whether restrictions are needed. Is it better to play offense by boosting domestic R&D or to play defense by trying to prevent Chinese biotechs from catching up? Is it even possible to slow China’s advance? Now, the debate has turned to the impact of the proposed rule, which is more aggressive than some anticipated. A Treasury official said licensing deals are exempt, but that exemption is at the heart of disagreements over the effects of the proposal. The Trump administration will require pharmacy benefit managers to disclose details on how they get paid as part of an accelerating push to overhaul the industry, reports. Under a new regulation the U.S. Department of Labor expects to release on Thursday, PBMs will have to provide clients with granular information about prices they pay for medicines, as well as payments they receive from drugmakers. The new regulation, which will take effect in July and apply to self-insured employers, will require PBMs to disclose rebates and other types of payment from drugmakers, including any that might lead patients to be steered to certain drugs over others. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe